ZNF232-AS1: ZNF232-AS1 is a long non-coding RNA (lncRNA) that has been implicated in hepatocellular carcinoma (HCC) and has the potential to predict the response to immunotherapy in HCC patients [PMC9857215]. Expression levels of ZNF232-AS1 were found to be higher in HCC tissues compared to normal tissues [PMC9263208]. The expression profile of ZNF232-AS1, along with other lncRNAs, was validated using qRT-PCR, and their levels were significantly higher in HCC tissues [PMC9263208]. ZNF232-AS1 expression was also found to be significantly different between normal liver cell lines and liver cancer cell lines [PMC10120187]. The significance of ZNF232-AS1 lies in its novelty and potential as a research direction for further investigation [PMC10120187]. In a prognostic model for HCC, ZNF232-AS1 was included as one of the lncRNAs used to calculate risk scores for patients [PMC10120187]. Additionally, ZNF232-AS1 was differentially expressed between mutant and wild-type groups for five driver genes associated with HCC [PMC9428707]. Furthermore, the expression of ZNF232-AS1 was found to be correlated with specific immune cell types in HCC [PMC9428707]. References: [PMC9857215] - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857215/ [PMC9263208] - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263208/ [PMC10120187] - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120187/ [PMC9428707] - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428707/